SCHEMBL851630

SCHEMBL851630

CC(C(=O)C(=O)O)c1ccccc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGS2 P35354 3/20 0.52
CES2 O00748 1/20 0.48
CES1 P23141 1/20 0.48
CYP2D6 P10635 1/20 0.46
SRC P12931 1/20 0.46
FAAH O00519 1/20 0.46
LMNA P02545 3/20 0.44
GRM7 Q14831 2/20 0.44
MAPK1 P28482 2/20 0.44
BCHE P06276 1/20 0.44
HTR1A P08908 1/20 0.44
ADRB3 P13945 1/20 0.44
HTR2A P28223 1/20 0.44
HTR2C P28335 1/20 0.44
DRD3 P35462 1/20 0.44
HTR2B P41595 1/20 0.44
HTR6 P50406 1/20 0.44
POLB P06746 1/20 0.44
MAPT P10636 2/20 0.44
PTGS1 P23219 2/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7973447 1.00 PTGS2 (0.52) PTGS2CES2CES1CYP2D6SRC
SCHEMBL29273241 1.00 PTGS2 (0.52) PTGS2CES2CES1CYP2D6SRC
SCHEMBL25287081 0.98 PTGS2 (0.50) PTGS2CES2CES1CYP2D6SRC
Boric Acid SCHEMBL28990244 0.94 PTGS2 (0.47) PTGS2CES2CES1CYP2D6SRC
Lithium Ion SCHEMBL30668805 0.90 PTGS2 (0.44) PTGS2CES2CES1CYP2D6SRC
Lithium Ion SCHEMBL30276146 0.88 PTGS2 (0.43) PTGS2CES2CES1CYP2D6FAAH
SCHEMBL11738135 0.87 PTGS2 (0.71) PTGS2MAPTSMN1; SMN2
SCHEMBL9577330 0.84 CYP2C9 (0.52) PTGS2CYP2D6LMNAMAPK1ADRB3
SCHEMBL10443247 0.82 PTGS1 (0.54) PTGS2CYP2D6LMNAPTGS1SMN1; SMN2
SCHEMBL11450473 0.82 LMNA (0.50) PTGS2LMNAADRB3HTR2APTGS1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 82 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119306681-A Synthesis method of 3-oxazoline-5-ketone and derivative thereof 湖南医药学院 2025-01-14 CN claimed
US-20030083380-A1 Method of using hydroxycarboxylic acids or related compounds for treating skin changes asociated with intrinsic and extrinsic aging YU RUEY J (US) 2003-05-01 US claimed
EP-0273202-B1 Use of hydroxycarboxylic acids to enhance therapeutic effects of topical compositions for fungal infections and pigmented spots. SCOTT EUGENE J VAN (US) 1995-06-21 EP claimed
JP-1121298-A None JP disclosed
JP-2000294-A None JP disclosed
US-20250369029-A1 METHOD FOR PRODUCING AMINO ACID AND PEPTIDE COMPOUND, USING ENZYME AND ADDITIVE CHUGAI PHARMACEUTICAL CO LTD (JP) 2025-12-04 US disclosed
US-12428403-B2 N-(heterocyclyl and heterocyclylalkyl)-3-benzylpyridin-2-amine derivatives as SSTR4 agonists TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2025-09-30 US disclosed
EP-4520829-A1 METHOD FOR PRODUCING AMINO ACID AND PEPTIDE COMPOUND, USING ENZYME AND ADDITIVE CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2025-03-12 EP disclosed
CN-119156450-A Method for producing amino acid and peptide compounds using enzymes and additives 中外制药株式会社 2024-12-17 CN disclosed
CN-115485273-B N- (heterocyclyl and heterocyclylalkyl) -3-benzyl pyridin-2-amine derivatives as SSTR4 agonists 武田药品工业株式会社 2024-08-13 CN disclosed
WO-2023219156-A1 METHOD FOR PRODUCING AMINO ACID AND PEPTIDE COMPOUND, USING ENZYME AND ADDITIVE 中外製薬株式会社 2023-11-16 WO disclosed
EP-0407588-B1 PROCESS FOR PRODUCING 2-OXO-3-AROMATIC CARBOXYLIC ACID DERIVATIVES SAGAMI CHEM RES (JP) 1993-12-08 EP disclosed
US-5028738-A Process for producing 2-oxo-3-aromatic carboxylic acid derivatives SAGAMI CHEMICAL RESEARCH CENTER (JP) 1991-07-02 US disclosed
EP-0407588-A1 PROCESS FOR PRODUCING 2-OXO-3-AROMATIC CARBOXYLIC ACID DERIVATIVES SAGAMI CHEMICAL RESEARCH CENTER (JP) 1991-01-16 EP disclosed
EP-0386243-A1 PLATINUM (II) COMPLEXES SAGAMI CHEMICAL RESEARCH CENTER (JP) 1990-09-12 EP disclosed
JP-H02294-A PLATINUM COORDINATION COMPOUND SAGAMI CHEM RES CENTER 1990-01-05 JP disclosed
JP-H01121298-A PRODUCTION OF N-SUBSTITUTED-AMINO ACID DERIVATIVE SAGAMI CHEM RES CENTER 1989-05-12 JP disclosed
EP-0076721-B1 PROCESS FOR THE CARBONYLATION OF SECONDARY BENZYL HALIDES Montedison S.p.A. (IT) 1985-02-06 EP disclosed
EP-0076721-A1 Process for the carbonylation of secondary benzyl halides Montedison S.p.A. (IT) 1983-04-13 EP disclosed
EP-0048159-A2 Novel carboxyalkyl peptides and thioethers and ethers of peptides as antihypertensive agents UNIVERSITY OF MIAMI (US) 1982-03-24 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12428403-B2 N-(heterocyclyl and heterocyclylalkyl)-3-benzylpyridin-2-amine derivatives as SSTR4 agonists SSTR4, SSTR3, SSTR1 PTGS2 2958/4885CES2 1741/4885CES1 2684/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.